Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-BiTS biweekly trifluridine/tipiracil plus bevacizumab dose-escalation study in refractory metastatic colorectal cancer
jRCTs041220085Phase 2Completed
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil and bevacizumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC). Primary endpoint: Disease control rate. Started Nov 2022; status: completed.
02
Drugs
trifluridine + tipiracilbevacizumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on jRCTs041220085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220085.